Physicians' Academy for Cardiovascular Education

New evidence in the treatment of hyperphosphatemia

3' education - Apr. 4, 2012

Dr. Mario Gennaro Cozzolino, University of Milan, Italy discusses the role of phosphate binders in the treatment of hyperphosphatemia. Phosphate has a central role in patients with chronic kidney disease, especially increasing their cardiovascular risk, according to dr. Cozzolino. He gives some practical advices with respect to phosphate binders. Lanthanum has a “very high efficacy in vitro and in vivo, with lower side effects”.

About the speaker

Mario Cozzolino, MD, PhD is an Assistant Professor in Nephrology at School of Medicine, DMCO, University of Milan, Italy. He is the Vice-Director and Chief of the Renal Unit, and the Director of the Laboratory of Experimental Nephrology at San Paolo Hospital, Milan, Italy. He is a member of European Dialysis Transplant Association and Italian Society of Nephrology. 1999-2002: Research Assistant in Vitamin D Laboratory, Renal Division, Department of Internal Medicine, School of Medicine, Washington University, St. Louis, MO – USA. Director: Eduardo Slatopolsky, MD. He has organized several congresses and meetings in the area of mineral metabolism and renal disease. His areas of interest are the mechanisms of pathogenesis of secondary hyperparathyroidism, renal osteodystrophy, and vascular calcification in CKD patients. Recently, he started to study the genetic polymorphism of proteins involved in the molecular mechanisms of vascular calcification in CKD. Finally, he is deeply involved in developing new treatments of secondary hyperparathyroidism and hyperphosphatemia in CKD patients. In the last 10 years, he has been involved as Principal Investigator in 6 International Clinical Trials on the Treatment of Hyperphosphatemia and Secondary Hyperparathyroidism in CKD and ESRD Patients. In 2003, he received the Award during the World Congress of Nephrology in Berlin, as one on ten “WCN 2003 Awards for Best Abstracts”. He is Author of 125 publications on peer-reviewed Journals (Total Impact Factor 306; Citations 1612; H-Index 21; i-10 index 33). He also serves as Associate Editor for “Clinical Kidney Journal” and “Blood Purification” and as Peer Reviewer for 20 Medical Journals.

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: